ARTICLE | Company News
Mercachem, Almirall deal
January 6, 2017 9:35 PM UTC
Mercachem granted Almirall exclusive rights to cytokine blockers program to treat inflammatory skin diseases. Mercachem will receive €1 million ($1 million) up front and R&D funding and is eligible fo...